<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7310596\results\search\disease\results.xml">
  <result pre="0444 3298Medstar Union Memorial Hospital, [10], grid.413083.d0000 0000 9142 8600Ahmanson-UCLA" exact="Cardiomyopathy" post="Center, Ronald Reagan-UCLA Medical Center, [11], grid.240416.50000 0004 0608"/>
  <result pre="Ronald Reagan-UCLA Medical Center, [11], grid.240416.50000 0004 0608 1972John Ochsner" exact="Heart" post="and Vascular Institute, Ochsner Clinical School, The University of"/>
  <result pre="Medical Center, [11], grid.240416.50000 0004 0608 1972John Ochsner Heart and" exact="Vascular" post="Institute, Ochsner Clinical School, The University of Queensland School"/>
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="(WHO) declaration of COVID-19 as a global pandemic. Abstract Coronavirus" exact="disease" post="2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus"/>
  <result pre="global pandemic. Abstract Coronavirus disease 2019 (COVID-19), caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a global"/>
  <result pre="pandemic. Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), is now a global pandemic"/>
  <result pre="Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), is now a global pandemic with"/>
  <result pre="affected individuals in the modern era. Not only is the" exact="infection" post="inflicting significant morbidity and mortality, but there has also"/>
  <result pre="health care system and the economy. COVID-19 typically presents as" exact="viral pneumonia," post="occasionally leading to acute respiratory distress syndrome (ARDS) and"/>
  <result pre="economy. COVID-19 typically presents as viral pneumonia, occasionally leading to" exact="acute" post="respiratory distress syndrome (ARDS) and death. However, emerging evidence"/>
  <result pre="COVID-19 typically presents as viral pneumonia, occasionally leading to acute" exact="respiratory" post="distress syndrome (ARDS) and death. However, emerging evidence suggests"/>
  <result pre="presents as viral pneumonia, occasionally leading to acute respiratory distress" exact="syndrome" post="(ARDS) and death. However, emerging evidence suggests that it"/>
  <result pre="evidence suggests that it has a significant impact on the" exact="cardiovascular" post="(CV) system by direct myocardial damage, severe systemic inflammatory"/>
  <result pre="on the cardiovascular (CV) system by direct myocardial damage, severe" exact="systemic" post="inflammatory response, hypoxia, right heart strain secondary to ARDS"/>
  <result pre="by direct myocardial damage, severe systemic inflammatory response, hypoxia, right" exact="heart" post="strain secondary to ARDS and lung injury, and plaque"/>
  <result pre="myocardial damage, severe systemic inflammatory response, hypoxia, right heart strain" exact="secondary" post="to ARDS and lung injury, and plaque rupture secondary"/>
  <result pre="strain secondary to ARDS and lung injury, and plaque rupture" exact="secondary" post="to inflammation. Primary cardiac manifestations include acute myocarditis, myocardial"/>
  <result pre="ARDS and lung injury, and plaque rupture secondary to inflammation." exact="Primary" post="cardiac manifestations include acute myocarditis, myocardial infarction, arrhythmia, and"/>
  <result pre="and plaque rupture secondary to inflammation. Primary cardiac manifestations include" exact="acute" post="myocarditis, myocardial infarction, arrhythmia, and abnormal clotting. Several consensus"/>
  <result pre="rupture secondary to inflammation. Primary cardiac manifestations include acute myocarditis," exact="myocardial infarction," post="arrhythmia, and abnormal clotting. Several consensus documents have been"/>
  <result pre="clotting. Several consensus documents have been released to help manage" exact="CV disease" post="during this pandemic. In this review, we summarize key"/>
  <result pre="Several consensus documents have been released to help manage CV" exact="disease" post="during this pandemic. In this review, we summarize key"/>
  <result pre="cardiac manifestations, their management, and future implications. Key Points Coronavirus" exact="disease" post="2019 (COVID-19) has a significant impact on the cardiovascular"/>
  <result pre="Coronavirus disease 2019 (COVID-19) has a significant impact on the" exact="cardiovascular" post="(CV) system, both directly and indirectly. COVID-19 infection utilizes"/>
  <result pre="on the cardiovascular (CV) system, both directly and indirectly. COVID-19" exact="infection" post="utilizes the angiotensin-converting enzyme 2 receptor for entry into"/>
  <result pre="the angiotensin-converting enzyme 2 receptor for entry into the cell" exact="Infection" post="can cause several CV syndromes, including myocardial damage, acute"/>
  <result pre="cell Infection can cause several CV syndromes, including myocardial damage," exact="acute" post="coronary syndrome, and arrhythmia. COVID-19 can result in hypercoagulability,"/>
  <result pre="syndrome, and arrhythmia. COVID-19 can result in hypercoagulability, resulting in" exact="venous thromboembolism" post="and pulmonary embolism, with consequent right ventricular dysfunction or"/>
  <result pre="COVID-19 can result in hypercoagulability, resulting in venous thromboembolism and" exact="pulmonary embolism," post="with consequent right ventricular dysfunction or failure. Clinicians should"/>
  <result pre="resulting in venous thromboembolism and pulmonary embolism, with consequent right" exact="ventricular dysfunction" post="or failure. Clinicians should also be aware of the"/>
  <result pre="CV effects of drugs used for COVID-19 treatment. Introduction Coronavirus" exact="disease" post="2019 (COVID-19) is a rapidly spreading novel infectious disease"/>
  <result pre="Introduction Coronavirus disease 2019 (COVID-19) is a rapidly spreading novel" exact="infectious disease" post="of the human respiratory system caused by a newly"/>
  <result pre="Coronavirus disease 2019 (COVID-19) is a rapidly spreading novel infectious" exact="disease" post="of the human respiratory system caused by a newly"/>
  <result pre="is a rapidly spreading novel infectious disease of the human" exact="respiratory" post="system caused by a newly discovered enveloped RNA Î²-coronavirus"/>
  <result pre="caused by a newly discovered enveloped RNA Î²-coronavirus named severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. Coronavirus has been"/>
  <result pre="by a newly discovered enveloped RNA Î²-coronavirus named severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) [1]. Coronavirus has been responsible"/>
  <result pre="a newly discovered enveloped RNA Î²-coronavirus named severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) [1]. Coronavirus has been responsible for"/>
  <result pre="for previous epidemics, such as SARS-CoV and the Middle East" exact="Respiratory" post="Syndrome (MERS)-CoV (TableÂ 1). Since diagnosis of the index"/>
  <result pre="previous epidemics, such as SARS-CoV and the Middle East Respiratory" exact="Syndrome" post="(MERS)-CoV (TableÂ 1). Since diagnosis of the index case,"/>
  <result pre="in Wuhan, Hubei Province, China, in December 2019 [2], the" exact="disease" post="has spread to involve more than 200 countries. As"/>
  <result pre="more than 200 countries. As of 29 May 2020, the" exact="total" post="number of cases in the US was 1,719,827, including"/>
  <result pre="diagnosed. Given the substantial morbidity and mortality caused by this" exact="disease" post="within a short timeframe and the high rate of"/>
  <result pre="substantial morbidity and mortality caused by this disease within a" exact="short" post="timeframe and the high rate of human-to-human transmission, the"/>
  <result pre="on 11 March 2020 [4]. Table 1 Timeline of coronavirus" exact="infection" post="affecting humans 1965: Tyrrell and Bynoe1 identified a virus"/>
  <result pre="1965: Tyrrell and Bynoe1 identified a virus named B814 2002â€&quot;2003:" exact="Severe" post="acute respiratory syndrome (SARS) 2012: Middle East Respiratory Syndrome"/>
  <result pre="Tyrrell and Bynoe1 identified a virus named B814 2002â€&quot;2003: Severe" exact="acute" post="respiratory syndrome (SARS) 2012: Middle East Respiratory Syndrome 2019â€&quot;2020:"/>
  <result pre="and Bynoe1 identified a virus named B814 2002â€&quot;2003: Severe acute" exact="respiratory" post="syndrome (SARS) 2012: Middle East Respiratory Syndrome 2019â€&quot;2020: Covid-19"/>
  <result pre="Bynoe1 identified a virus named B814 2002â€&quot;2003: Severe acute respiratory" exact="syndrome" post="(SARS) 2012: Middle East Respiratory Syndrome 2019â€&quot;2020: Covid-19 (the"/>
  <result pre="B814 2002â€&quot;2003: Severe acute respiratory syndrome (SARS) 2012: Middle East" exact="Respiratory" post="Syndrome 2019â€&quot;2020: Covid-19 (the illness caused by SARS-CoV-2 infection)"/>
  <result pre="2002â€&quot;2003: Severe acute respiratory syndrome (SARS) 2012: Middle East Respiratory" exact="Syndrome" post="2019â€&quot;2020: Covid-19 (the illness caused by SARS-CoV-2 infection) First"/>
  <result pre="On 11 February 2020, the WHO Director-General announced that the" exact="disease" post="caused by this new CoV was â€˜COVID-19â€™ WHO raised"/>
  <result pre="March 2020 WHO declared COVID-19 a pandemic CDC Centers for" exact="Disease" post="Control and Prevention, CoV coronavirus, rRT-PCR real-time reverse-transcriptaseâ€&quot;polymerase-chain-reaction, WHO"/>
  <result pre="World Health Organization It is noteworthy that COVID-19 has a" exact="lower" post="fatality rate than the previous outbreak of SARS, but"/>
  <result pre="remarkable capacity to spread quickly, thus making it an ideal" exact="infection" post="to result in a pandemic. Our understanding of this"/>
  <result pre="infection to result in a pandemic. Our understanding of this" exact="disease" post="is still evolving; however, a substantial amount of data"/>
  <result pre="substantial amount of data has emerged recently indicating not just" exact="pulmonary" post="involvement but significant involvement, both direct and indirect, of"/>
  <result pre="involvement but significant involvement, both direct and indirect, of the" exact="cardiovascular" post="(CV) system [5â€&quot;7]. Interestingly, cardiac complications are not only"/>
  <result pre="utilizes the angiotensin-converting enzyme 2 (ACE2) receptor, abundant in the" exact="lower" post="respiratory tract, for entry into the cells. Importantly, ACE2"/>
  <result pre="the angiotensin-converting enzyme 2 (ACE2) receptor, abundant in the lower" exact="respiratory" post="tract, for entry into the cells. Importantly, ACE2 is"/>
  <result pre="Importantly, ACE2 is also expressed in the heart, intestinal epithelium," exact="vascular" post="endothelium, and the kidneys, making all of these organs"/>
  <result pre="fusion of the virus-cell membrane followed by the release of" exact="viral" post="RNA into the cytoplasm. This is followed by the"/>
  <result pre="the cytoplasm. This is followed by the translation of new" exact="viral" post="particles, with subsequent release to infect other cells [7,"/>
  <result pre="infect other cells [7, 8]. After the initial infection, the" exact="acute" post="disease progression can be divided into three distinct phases"/>
  <result pre="other cells [7, 8]. After the initial infection, the acute" exact="disease" post="progression can be divided into three distinct phases (early"/>
  <result pre="disease progression can be divided into three distinct phases (early" exact="infection" post="phase, pulmonary phase, and a hyperinflammation phase) with significant"/>
  <result pre="can be divided into three distinct phases (early infection phase," exact="pulmonary" post="phase, and a hyperinflammation phase) with significant overlap [9â€&quot;11]."/>
  <result pre="significant elevation of inflammatory markers, including interleukin (IL)-6, IL-2, IL-7," exact="tumor" post="necrosis factor (TNF)-Î±, interferon-inducible protein (IP)-10, monocyte chemoattractant protein"/>
  <result pre="(IL)-6, IL-2, IL-7, tumor necrosis factor (TNF)-Î±, interferon-inducible protein (IP)-10," exact="monocyte" post="chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1Î±, granulocyte colony"/>
  <result pre="The exact pathogenesis of cardiac involvement is not entirely clear." exact="Increased" post="cardiac biomarkers, including troponin T, have been shown to"/>
  <result pre="myocardial damage by the virus itself, hypoxic injury mediated by" exact="respiratory" post="failure, indirect injury mediated by cytokines secondary to systemic"/>
  <result pre="injury mediated by respiratory failure, indirect injury mediated by cytokines" exact="secondary" post="to systemic inflammatory response, myocardial infarction (MI) due to"/>
  <result pre="by respiratory failure, indirect injury mediated by cytokines secondary to" exact="systemic" post="inflammatory response, myocardial infarction (MI) due to plaque rupture"/>
  <result pre="indirect injury mediated by cytokines secondary to systemic inflammatory response," exact="myocardial infarction" post="(MI) due to plaque rupture secondary to systemic inflammation,"/>
  <result pre="systemic inflammatory response, myocardial infarction (MI) due to plaque rupture" exact="secondary" post="to systemic inflammation, the prothrombotic state produced by severe"/>
  <result pre="response, myocardial infarction (MI) due to plaque rupture secondary to" exact="systemic" post="inflammation, the prothrombotic state produced by severe systemic inflammation,"/>
  <result pre="(MI) due to plaque rupture secondary to systemic inflammation, the" exact="prothrombotic state" post="produced by severe systemic inflammation, and ischemia from myocardial"/>
  <result pre="secondary to systemic inflammation, the prothrombotic state produced by severe" exact="systemic" post="inflammation, and ischemia from myocardial supplyâ€&quot;demand mismatch (Fig.Â 1)."/>
  <result pre="inflammation, the prothrombotic state produced by severe systemic inflammation, and" exact="ischemia" post="from myocardial supplyâ€&quot;demand mismatch (Fig.Â 1). ACE2 receptor-mediated direct"/>
  <result pre="endothelial cells, and animal data suggest that their direct dysfunction" exact="secondary" post="to viral infection or secondary inflammation may precipitate MI"/>
  <result pre="and animal data suggest that their direct dysfunction secondary to" exact="viral infection" post="or secondary inflammation may precipitate MI [19, 20]. Fig."/>
  <result pre="animal data suggest that their direct dysfunction secondary to viral" exact="infection" post="or secondary inflammation may precipitate MI [19, 20]. Fig."/>
  <result pre="suggest that their direct dysfunction secondary to viral infection or" exact="secondary" post="inflammation may precipitate MI [19, 20]. Fig. 1 Schematic"/>
  <result pre="This figure describes the structure of the SARS-CoV-2. In the" exact="respiratory" post="system, the virus spike protein binds with the ACE2"/>
  <result pre="the virus spike protein binds with the ACE2 receptor in" exact="respiratory" post="epithelial cells and internalizes and forms a membrane fusion"/>
  <result pre="virus spike protein binds with the ACE2 receptor in respiratory" exact="epithelial" post="cells and internalizes and forms a membrane fusion complex,"/>
  <result pre="a membrane fusion complex, which causes the release of the" exact="viral" post="RNA into the host cell and results in respiratory"/>
  <result pre="the viral RNA into the host cell and results in" exact="respiratory" post="infection. Through different pathways, the virus induces the proinflammatory"/>
  <result pre="response by induction of T- and B-cells and synthesis of" exact="type I" post="IFNs, which limit the spread of the virus and"/>
  <result pre="storm, while induction of the macrophage causes ingestion of the" exact="viral" post="antigen [this image is generated with the help of"/>
  <result pre="image is generated with the help of Biorender]. SARS-CoV-2 severe" exact="acute" post="respiratory syndrome coronavirus 2, ACE2 angiotensin converting enzyme 2,"/>
  <result pre="is generated with the help of Biorender]. SARS-CoV-2 severe acute" exact="respiratory" post="syndrome coronavirus 2, ACE2 angiotensin converting enzyme 2, IFNs"/>
  <result pre="generated with the help of Biorender]. SARS-CoV-2 severe acute respiratory" exact="syndrome" post="coronavirus 2, ACE2 angiotensin converting enzyme 2, IFNs interferons,"/>
  <result pre="interferons, NK natural killer, TH17 T-helper 17, IL interleukin, TNF" exact="tumor" post="necrosis factor, MCP monocyte chemoattractant protein Clinical Manifestations The"/>
  <result pre="TH17 T-helper 17, IL interleukin, TNF tumor necrosis factor, MCP" exact="monocyte" post="chemoattractant protein Clinical Manifestations The median incubation period of"/>
  <result pre="also been reported as notable and somewhat specific symptoms. Upper" exact="respiratory" post="tract symptoms such as rhinorrhea are conspicuously less common."/>
  <result pre="rhinorrhea are conspicuously less common. Gastrointestinal symptoms, including nausea and" exact="diarrhea" post="[22, 23] are also less common. The initial experience"/>
  <result pre="approximately 81% of infected patients experience mild disease, with severe" exact="disease" post="developing in 14%. Pneumonia with acute respiratory distress syndrome"/>
  <result pre="patients experience mild disease, with severe disease developing in 14%." exact="Pneumonia" post="with acute respiratory distress syndrome (ARDS) is the most"/>
  <result pre="mild disease, with severe disease developing in 14%. Pneumonia with" exact="acute" post="respiratory distress syndrome (ARDS) is the most common severe"/>
  <result pre="disease, with severe disease developing in 14%. Pneumonia with acute" exact="respiratory" post="distress syndrome (ARDS) is the most common severe manifestation."/>
  <result pre="severe disease developing in 14%. Pneumonia with acute respiratory distress" exact="syndrome" post="(ARDS) is the most common severe manifestation. Critical illness"/>
  <result pre="(ARDS) is the most common severe manifestation. Critical illness with" exact="septic shock" post="and multi-organ dysfunction has been reported in 5% of"/>
  <result pre="multi-organ dysfunction has been reported in 5% of patients [13]." exact="Cardiac" post="Manifestations As previously discussed, cardiac injury is a common"/>
  <result pre="cardiac injury is a common problem associated with COVID-19 [24]." exact="Acute coronary syndrome" post="(ACS), arrhythmias, and blood pressure fluctuations have been reported"/>
  <result pre="is a common problem associated with COVID-19 [24]. Acute coronary" exact="syndrome" post="(ACS), arrhythmias, and blood pressure fluctuations have been reported"/>
  <result pre="to occur, in addition to cardiac dysfunction. The incidence of" exact="arrhythmia" post="has not been clearly reported, although it is expected"/>
  <result pre="25]. In a study conducted in Wuhan, cardiac conditions, including" exact="heart" post="failure (HF), contributed to 40% of the mortality, either"/>
  <result pre="of the mortality, either acting alone or in conjunction with" exact="respiratory" post="failure [15]. Cardiovascular Effects Previous viral epidemics have been"/>
  <result pre="or in conjunction with respiratory failure [15]. Cardiovascular Effects Previous" exact="viral" post="epidemics have been associated with a significant increase in"/>
  <result pre="a meta-analysis of patients admitted with COVID-19, the incidence of" exact="CV disease" post="(CVD) was 16.4% in non-intensive care unit (ICU) patients,"/>
  <result pre="meta-analysis of patients admitted with COVID-19, the incidence of CV" exact="disease" post="(CVD) was 16.4% in non-intensive care unit (ICU) patients,"/>
  <result pre="(TableÂ 2). Table 2 Summarizing published case studies showing baseline" exact="cardiovascular" post="comorbidities in COVID-affected patients Author Place of study Date"/>
  <result pre="comorbidities in COVID-affected patients Author Place of study Date accepted/published" exact="Total" post="no. of patients Mean age, years % of male"/>
  <result pre="patients Mean age, years % of male patients % of" exact="female" post="patients % of HTN % of DM % of"/>
  <result pre="2020 1591 63 82 18 49 17 21 NA CAD" exact="coronary artery disease," post="CVD cardiovascular disease, DM diabetes mellitus, HTN hypertension, NA"/>
  <result pre="1591 63 82 18 49 17 21 NA CAD coronary" exact="artery disease," post="CVD cardiovascular disease, DM diabetes mellitus, HTN hypertension, NA"/>
  <result pre="18 49 17 21 NA CAD coronary artery disease, CVD" exact="cardiovascular disease," post="DM diabetes mellitus, HTN hypertension, NA not available aOther"/>
  <result pre="21 NA CAD coronary artery disease, CVD cardiovascular disease, DM" exact="diabetes mellitus," post="HTN hypertension, NA not available aOther cardiac diseases include"/>
  <result pre="mellitus, HTN hypertension, NA not available aOther cardiac diseases include" exact="congestive heart failure," post="acute cardiac injury, arrhythmia bAcute cardiac injury cArrhythmia dEndocrine"/>
  <result pre="HTN hypertension, NA not available aOther cardiac diseases include congestive" exact="heart" post="failure, acute cardiac injury, arrhythmia bAcute cardiac injury cArrhythmia"/>
  <result pre="NA not available aOther cardiac diseases include congestive heart failure," exact="acute" post="cardiac injury, arrhythmia bAcute cardiac injury cArrhythmia dEndocrine system"/>
  <result pre="aOther cardiac diseases include congestive heart failure, acute cardiac injury," exact="arrhythmia" post="bAcute cardiac injury cArrhythmia dEndocrine system disease Myocardial Damage"/>
  <result pre="acute cardiac injury, arrhythmia bAcute cardiac injury cArrhythmia dEndocrine system" exact="disease" post="Myocardial Damage Cardiotropic viruses directly attack cardiac cells at"/>
  <result pre="attack cardiac cells at the initial phase, followed by a" exact="secondary" post="inflammatory response that can lead to further cardiac damage."/>
  <result pre="a role in the direct cardiac damage, as well as" exact="vascular" post="involvement in COVID-19 infection. In autopsies from the SARS"/>
  <result pre="In autopsies from the SARS outbreak in 2002, 35% of" exact="heart" post="samples revealed the presence of viral RNA in the"/>
  <result pre="in 2002, 35% of heart samples revealed the presence of" exact="viral" post="RNA in the myocardium, and it was associated with"/>
  <result pre="believed SARS-CoV-2 may share the same mechanism, with direct cardiac" exact="muscle" post="damage playing a role in both the myocarditis and"/>
  <result pre="direct cardiac muscle damage playing a role in both the" exact="myocarditis" post="and HF in COVID-19-infected individuals. Cardiac muscle involvement has"/>
  <result pre="role in both the myocarditis and HF in COVID-19-infected individuals." exact="Cardiac" post="muscle involvement has been evident by increased cardiac biomarkers"/>
  <result pre="in both the myocarditis and HF in COVID-19-infected individuals. Cardiac" exact="muscle" post="involvement has been evident by increased cardiac biomarkers in"/>
  <result pre="infiltrate in the myocardium, with related cardiomyocyte necrosis [43]. Finally," exact="acute" post="lung injury and ARDS result in right heart strain,"/>
  <result pre="[43]. Finally, acute lung injury and ARDS result in right" exact="heart" post="strain, with right ventricular (RV) dilation and dysfunction, and"/>
  <result pre="in COVID patients, which also correlated with the severity of" exact="disease" post="[50, 51]. EKG and echocardiographic findings, in conjunction with"/>
  <result pre="help in early risk stratification [52]. Although case reports of" exact="myocarditis" post="in COVID-19 patients exist, it is unclear whether the"/>
  <result pre="myocarditis in COVID-19 patients exist, it is unclear whether the" exact="myocarditis" post="is induced by the virus directly or results from"/>
  <result pre="an inflammatory response [53]. A case of myopericarditis complicated by" exact="cardiac tamponade" post="was also reported in the literature [54]. Isolated hemorrhagic"/>
  <result pre="by cardiac tamponade was also reported in the literature [54]." exact="Isolated" post="hemorrhagic pericardial effusion with tamponade without the features of"/>
  <result pre="tamponade was also reported in the literature [54]. Isolated hemorrhagic" exact="pericardial effusion" post="with tamponade without the features of myocarditis has also"/>
  <result pre="Isolated hemorrhagic pericardial effusion with tamponade without the features of" exact="myocarditis" post="has also been demonstrated [55]. Recently, two cases have"/>
  <result pre="[55]. Recently, two cases have been reported with apparent Takotsubo" exact="syndrome" post="in the setting of COVID infection [56, 57]. Although"/>
  <result pre="reported with apparent Takotsubo syndrome in the setting of COVID" exact="infection" post="[56, 57]. Although cardiac involvement usually occurs later in"/>
  <result pre="cardiac involvement usually occurs later in the course of COVID-19," exact="acute" post="HF secondary to myocardial involvement or previously existing cardiac"/>
  <result pre="usually occurs later in the course of COVID-19, acute HF" exact="secondary" post="to myocardial involvement or previously existing cardiac disease could"/>
  <result pre="COVID-19, acute HF secondary to myocardial involvement or previously existing" exact="cardiac disease" post="could be the presenting symptoms in COVID-19 infection in"/>
  <result pre="acute HF secondary to myocardial involvement or previously existing cardiac" exact="disease" post="could be the presenting symptoms in COVID-19 infection in"/>
  <result pre="existing cardiac disease could be the presenting symptoms in COVID-19" exact="infection" post="in almost one-quarter of patients. The management of myocardial"/>
  <result pre="COVID patients with HF [58]. Coronary Ischemia/Infarction Coronary involvement and" exact="ischemia" post="have been seen, including ST-elevation myocardial infarction (STEMI) and"/>
  <result pre="Ischemia/Infarction Coronary involvement and ischemia have been seen, including ST-elevation" exact="myocardial infarction" post="(STEMI) and non-ST-elevation myocardial infarction (NSTEMI), with several mechanisms"/>
  <result pre="have been seen, including ST-elevation myocardial infarction (STEMI) and non-ST-elevation" exact="myocardial infarction" post="(NSTEMI), with several mechanisms explaining coronary artery involvement. As"/>
  <result pre="mechanisms explaining coronary artery involvement. As ACE2 is expressed in" exact="vascular" post="endothelial cells, direct viral infection can lead to plaque"/>
  <result pre="involvement. As ACE2 is expressed in vascular endothelial cells, direct" exact="viral infection" post="can lead to plaque instability and type 1 MI."/>
  <result pre="As ACE2 is expressed in vascular endothelial cells, direct viral" exact="infection" post="can lead to plaque instability and type 1 MI."/>
  <result pre="cells, direct viral infection can lead to plaque instability and" exact="type 1" post="MI. Plaque instability and rupture may also result from"/>
  <result pre="Plaque instability and rupture may also result from the severe" exact="systemic" post="inflammatory response in the third phase of the disease."/>
  <result pre="the third phase of the disease. COVID-19 can additionally precipitate" exact="type II" post="MI by demand ischemia as patients get sicker. Hypoxia"/>
  <result pre="disease. COVID-19 can additionally precipitate type II MI by demand" exact="ischemia" post="as patients get sicker. Hypoxia secondary to lung involvement,"/>
  <result pre="II MI by demand ischemia as patients get sicker. Hypoxia" exact="secondary" post="to lung involvement, and fever and tachycardia secondary to"/>
  <result pre="sicker. Hypoxia secondary to lung involvement, and fever and tachycardia" exact="secondary" post="to sepsis, further worsen the cardiac function. Coronary artery"/>
  <result pre="been described. Such small vessel involvement can be due to" exact="systemic" post="vasculitis or to microembolization from ACS or disseminated hypercoagulability"/>
  <result pre="described. Such small vessel involvement can be due to systemic" exact="vasculitis" post="or to microembolization from ACS or disseminated hypercoagulability impairing"/>
  <result pre="Currently, multiple factors have been sources of delay for a" exact="primary" post="percutaneous coronary intervention (PCI) approach, including determining whether STEMI"/>
  <result pre="(PCI) approach, including determining whether STEMI or COVID is the" exact="primary" post="problem, and deciphering mimickers of STEMI, such as Takotsubo"/>
  <result pre="STEMI, such as Takotsubo cardiomyopathy, myocarditis, RV failure, or massive" exact="pulmonary embolism" post="(PE). In the emergency department, screening for COVID infection"/>
  <result pre="pulmonary embolism (PE). In the emergency department, screening for COVID" exact="infection" post="may take some time, and, within the catheterization laboratory,"/>
  <result pre="to the care of these patients. A small study evaluating" exact="primary" post="PCI in seven patients presenting with STEMI calculated the"/>
  <result pre="CI 1.51â€&quot;2.39; pâ€‰ 60]. According to recent statements by the" exact="American" post="College of Cardiology (ACC) Interventional Council and Society for"/>
  <result pre="(SCAI) regarding the management of STEMI during the COVID-19 pandemic," exact="primary" post="PCI should remain the standard in these patients, with"/>
  <result pre="reserved for patients with relative contraindications or those with severe" exact="bilateral" post="COVID pneumonia (PNR) or ARDS, given the poor overall"/>
  <result pre="patients with relative contraindications or those with severe bilateral COVID" exact="pneumonia" post="(PNR) or ARDS, given the poor overall prognosis (Fig.Â"/>
  <result pre="blood pressure, GI gastrointestinal, GU genitourinary, H/O history of, HR" exact="heart" post="rate, ICH intracranial hemorrhage, LA left arm, PCI percutaneous"/>
  <result pre="intervention, RA right arm, SBP systolic blood pressure, STEMI ST-elevation" exact="myocardial infarction." post="*High risk individuals: 1. HR &amp;gt;Â 100/min and SBP"/>
  <result pre="advantage of evaluating the lung parenchyma for signs of COVID" exact="pneumonia" post="or other etiologies of decompensation, such as PE with"/>
  <result pre="at some institutions for patients in whom there are both" exact="pulmonary" post="and cardiac manifestations, especially in the setting of fever."/>
  <result pre="pulmonary and cardiac manifestations, especially in the setting of fever." exact="Arrhythmias" post="The incidence of arrhythmia is currently unknown in COVID-19"/>
  <result pre="especially in the setting of fever. Arrhythmias The incidence of" exact="arrhythmia" post="is currently unknown in COVID-19 patients, with preliminary data"/>
  <result pre="due to clinical decompensation, fever, or sepsis. The cause of" exact="arrhythmia" post="could be myocarditis, hypoxia, or electrolyte derangement seen in"/>
  <result pre="rarely seen in clinical practice in patients routinely treated for" exact="malaria" post="and rheumatological conditions such as systemic lupus erythematosus [62,"/>
  <result pre="patients routinely treated for malaria and rheumatological conditions such as" exact="systemic" post="lupus erythematosus [62, 63], but the incidence alongside COVID-19,"/>
  <result pre="routinely treated for malaria and rheumatological conditions such as systemic" exact="lupus erythematosus" post="[62, 63], but the incidence alongside COVID-19, especially in"/>
  <result pre="severe cases, remains unclear. According to the recommendations from the" exact="Heart" post="Rhythm Society released recently in collaboration with the ACC"/>
  <result pre="patient groups. These include individuals with a known history of" exact="long QT syndrome," post="those with deranged renal function, those with electrolyte abnormalities"/>
  <result pre="with deranged renal function, those with electrolyte abnormalities such as" exact="hypokalemia" post="and hypomagnesemia, and those prescribed other QTc-prolonging drugs [64]."/>
  <result pre="FDA has mentioned the risk of this combination therapy [66]." exact="Arrhythmias" post="leading to cardiac arrest deserve special mention. Cardiopulmonary resuscitation"/>
  <result pre="the risk of this combination therapy [66]. Arrhythmias leading to" exact="cardiac arrest" post="deserve special mention. Cardiopulmonary resuscitation (CPR) with chest compressions"/>
  <result pre="to cardiac arrest deserve special mention. Cardiopulmonary resuscitation (CPR) with" exact="chest" post="compressions is very high risk for aerosolization of virus,"/>
  <result pre="no disconnections in the closed-circuit should be the goal [67]." exact="Venous Thromboembolism" post="An increased risk of blood clot formation resulting from"/>
  <result pre="[68]. Similarly, COVID-19 has been associated with a hypercoagulable state." exact="Dysfunction" post="of endothelial cells induced by infection results in excess"/>
  <result pre="with a hypercoagulable state. Dysfunction of endothelial cells induced by" exact="infection" post="results in excess thrombin generation and fibrinolysis shutdown. The"/>
  <result pre="infection results in excess thrombin generation and fibrinolysis shutdown. The" exact="hypoxia" post="found in severe COVID-19 can also stimulate thrombosis through"/>
  <result pre="shutdown. The hypoxia found in severe COVID-19 can also stimulate" exact="thrombosis" post="through increasing blood viscosity. A hypoxia-inducible transcription factor-dependent signaling"/>
  <result pre="by Panigada et al. showed an increased risk of venous" exact="thrombosis" post="in COVID-19-affected individuals [70]. One study involving 184 patients"/>
  <result pre="study involving 184 patients showed CT angiography and/or ultrasonography confirmed" exact="venous thromboembolism" post="(VTE) in 27% of patients and arterial thrombotic events"/>
  <result pre="PE in COVID patients is challenging. The International Society on" exact="Thrombosis" post="and Hemostasis (ISTH) advocates the use of laboratory tests,"/>
  <result pre="contrast use in the setting of poor cardiac output and" exact="hypoxia" post="from COVID-19 [73]. Maintaining isolation while doing the tests"/>
  <result pre="severe COVID-19, anticoagulant therapy, mainly with LMWH, was associated with" exact="lower" post="mortality in patients with markedly elevated D-dimer [75]. The"/>
  <result pre="heparin may be superior in critically ill patients with underlying" exact="renal failure," post="which is a contraindication to LMWH. Interestingly, in vivo"/>
  <result pre="a contraindication to LMWH. Interestingly, in vivo models of coronavirus" exact="infection" post="have shown that administration of unfractionated heparin functions as"/>
  <result pre="administration of unfractionated heparin functions as a decoy receptor, reducing" exact="viral" post="infectivity and potentially augmenting viral clearance [76]. Heparin also"/>
  <result pre="as a decoy receptor, reducing viral infectivity and potentially augmenting" exact="viral" post="clearance [76]. Heparin also has anti-inflammatory effects, reduces myocardial"/>
  <result pre="in animal models [77]. Tissue plasminogen activator (TPA) has shown" exact="transient" post="improvement in a case series but there is still"/>
  <result pre="that study [81]. Recently published clinical data have suggested that" exact="systemic" post="anticoagulation may be associated with positive outcomes among patients"/>
  <result pre="Medications It is estimated that 15â€&quot;30% of COVID-19 patients have" exact="hypertension" post="(HTN) [16]. Indeed, a meta-analysis (nâ€‰=â€‰46,248) including eight studies"/>
  <result pre="have an increased number of receptors. Although some have reported" exact="obesity" post="to be a risk factor for COVID infection, more"/>
  <result pre="(ARBs), and the predominant role of ACE2 receptors in the" exact="disease" post="pathogenesis, there has been some concern surrounding the use"/>
  <result pre="these medications in COVID-19 patients. Animal data have supported that" exact="chronic" post="use of ARBs elevates ACE2 receptor expression, and elevated"/>
  <result pre="et al. recently published a retrospective, multicenter study including 1128" exact="adult" post="patients with COVID-19 and found a lower risk of"/>
  <result pre="study including 1128 adult patients with COVID-19 and found a" exact="lower" post="risk of all-cause mortality with inpatient use of ACEIs/ARBs"/>
  <result pre="recently published studies, showing no evidence of increased risk of" exact="infection" post="or inpatient mortality in COVID-affected patients who continued on"/>
  <result pre="randomized clinical trials and are postulated to work by blocking" exact="viral" post="entry into cells through endosomal trafficking and by exerting"/>
  <result pre="cause QTc prolongation [93]. Ribavirin has the potential to cause" exact="hemolytic anemia" post="in high doses [94], which can also increase CVD"/>
  <result pre="QTc prolongation [93]. Ribavirin has the potential to cause hemolytic" exact="anemia" post="in high doses [94], which can also increase CVD"/>
  <result pre="patients Cardiovascular adverse effects Chloroquine and hydroxychloroquine 1. Inhibits the" exact="viral" post="entry through endosomal trafficking 2. Immunomodulatory effect through cytokine"/>
  <result pre="Immunomodulatory effect through cytokine attenuation QTc prolongation, bundle branch block," exact="AV block," post="ventricular arrhythmias, Torsades de pointe Lopinavir/ritonavir Lopinavir inhibits viral"/>
  <result pre="AV block, ventricular arrhythmias, Torsades de pointe Lopinavir/ritonavir Lopinavir inhibits" exact="viral" post="protease Ritonavir inhibits CYP3A metabolism, increasing the half-life of"/>
  <result pre="CYP3A metabolism, increasing the half-life of lopinavir Conduction abnormalities Remdesivir" exact="Viral" post="RNA polymerase inhibitor No serious cardiac adverse effects Ribavirin"/>
  <result pre="RNA polymerase inhibitor No serious cardiac adverse effects Ribavirin Inhibits" exact="viral" post="RNA and DNA replication Hemolytic anemia Corticosteroids Anti-inflammatory Electrolyte"/>
  <result pre="cardiac adverse effects Ribavirin Inhibits viral RNA and DNA replication" exact="Hemolytic" post="anemia Corticosteroids Anti-inflammatory Electrolyte imbalance and hypertension Anticytokine agents"/>
  <result pre="adverse effects Ribavirin Inhibits viral RNA and DNA replication Hemolytic" exact="anemia" post="Corticosteroids Anti-inflammatory Electrolyte imbalance and hypertension Anticytokine agents (tocilizumab)"/>
  <result pre="and DNA replication Hemolytic anemia Corticosteroids Anti-inflammatory Electrolyte imbalance and" exact="hypertension" post="Anticytokine agents (tocilizumab) Inhibits IL-6 and cytokine storm Rare"/>
  <result pre="hypertension Anticytokine agents (tocilizumab) Inhibits IL-6 and cytokine storm Rare" exact="hypertension" post="Immunoglobulin therapy Antibodies against the virus in the convalescent"/>
  <result pre="therapy Antibodies against the virus in the convalescent plasma Transfusion-related" exact="acute" post="lung injury leading to cardiopulmonary failure Low-molecular-weight heparin Anticoagulation"/>
  <result pre="cardiopulmonary failure Low-molecular-weight heparin Anticoagulation Bleeding in the cerebrovascular space," exact="heparin-induced thrombocytopenia," post="deep vein thrombosis, and pulmonary embolism Extracorporeal membrane oxygenation"/>
  <result pre="Low-molecular-weight heparin Anticoagulation Bleeding in the cerebrovascular space, heparin-induced thrombocytopenia," exact="deep vein thrombosis," post="and pulmonary embolism Extracorporeal membrane oxygenation Assisted extracorporeal circulation"/>
  <result pre="in the cerebrovascular space, heparin-induced thrombocytopenia, deep vein thrombosis, and" exact="pulmonary embolism" post="Extracorporeal membrane oxygenation Assisted extracorporeal circulation and physiologic gas"/>
  <result pre="Assisted extracorporeal circulation and physiologic gas exchange in cardiopulmonary failure" exact="Distal" post="ischemia and thrombosis Mechanical ventilation Assist spontaneous breathing in"/>
  <result pre="extracorporeal circulation and physiologic gas exchange in cardiopulmonary failure Distal" exact="ischemia" post="and thrombosis Mechanical ventilation Assist spontaneous breathing in CoVID-19-induced"/>
  <result pre="and physiologic gas exchange in cardiopulmonary failure Distal ischemia and" exact="thrombosis" post="Mechanical ventilation Assist spontaneous breathing in CoVID-19-induced ARDS Decreased"/>
  <result pre="ventilation Assist spontaneous breathing in CoVID-19-induced ARDS Decreased cardiac output," exact="respiratory" post="alkalosis, increased intracranial pressure ARDS acute respiratory distress syndrome,"/>
  <result pre="ARDS Decreased cardiac output, respiratory alkalosis, increased intracranial pressure ARDS" exact="acute" post="respiratory distress syndrome, AV atrioventricular, CYP cytochrome P450, IL"/>
  <result pre="Decreased cardiac output, respiratory alkalosis, increased intracranial pressure ARDS acute" exact="respiratory" post="distress syndrome, AV atrioventricular, CYP cytochrome P450, IL interleukin"/>
  <result pre="phase of infection, as described herein, long-term sequelae of the" exact="disease" post="remain a possibility despite complete viral clearance. Previous epidemics"/>
  <result pre="herein, long-term sequelae of the disease remain a possibility despite" exact="complete" post="viral clearance. Previous epidemics from similar viruses can be"/>
  <result pre="long-term sequelae of the disease remain a possibility despite complete" exact="viral" post="clearance. Previous epidemics from similar viruses can be informative"/>
  <result pre="healthy volunteers [95]. This metabolic change was subsequently associated with" exact="hyperlipidemia" post="and also with impaired glucose metabolism. Multiple studies have"/>
  <result pre="subsequently associated with hyperlipidemia and also with impaired glucose metabolism." exact="Multiple" post="studies have reported avascular necrosis as a long-term complication"/>
  <result pre="and also with impaired glucose metabolism. Multiple studies have reported" exact="avascular necrosis" post="as a long-term complication from the corticosteroids prescribed to"/>
  <result pre="leading to these metabolic changes as a result of the" exact="viral infection" post="remains unknown. Osteonecrosis is independently associated with an increased"/>
  <result pre="to these metabolic changes as a result of the viral" exact="infection" post="remains unknown. Osteonecrosis is independently associated with an increased"/>
  <result pre="corticosteroids and warrants further exploration [98, 99]. Psychiatric morbidities, including" exact="chronic fatigue syndrome," post="were also reported in patients who recovered from SARS"/>
  <result pre="[100]. Given the strong association between psychiatric conditions, such as" exact="depression" post="and chronic fatigue syndrome, and CVD, such as chronic"/>
  <result pre="the strong association between psychiatric conditions, such as depression and" exact="chronic fatigue syndrome," post="and CVD, such as chronic HF and cardiac arrhythmias,"/>
  <result pre="as depression and chronic fatigue syndrome, and CVD, such as" exact="chronic" post="HF and cardiac arrhythmias, the evidence backing long-term CV"/>
  <result pre="cardiac arrhythmias, the evidence backing long-term CV sequelae of these" exact="infections" post="appears compelling [101â€&quot;104]. The outbreak of the pandemic has"/>
  <result pre="this pandemic, and potentially an increased number of decompensated patients" exact="secondary" post="to non-compliance, delayed elective procedures, and completed or late-presenting"/>
  <result pre="late-presenting MI. A recent analysis showed a 38% decrease in" exact="primary" post="PCI in the US during the COVID-19 pandemic, which"/>
  <result pre="going to the hospital early for fear of contracting the" exact="infection" post="in the hospital, misdiagnosis of STEMI, and more use"/>
  <result pre="in the number of post-MI complications, such as mechanical complications," exact="cardiogenic shock," post="cardiac rupture, post-MI angina, and reinfarction, that were not"/>
  <result pre="Italy has been noted [108]. Interestingly, the incidence of out-of-hospital" exact="cardiac arrest" post="has increased [109]. Masking of symptoms such as shortness"/>
  <result pre="increased [109]. Masking of symptoms such as shortness of breath," exact="chest" post="tightness, underlying poor clinical status of patients secondary to"/>
  <result pre="of breath, chest tightness, underlying poor clinical status of patients" exact="secondary" post="to COVID, and fear of accessing the health care"/>
  <result pre="S. Naidu contributed equally. Compliance with Ethical Standards Funding No" exact="external" post="funding was used in the preparation of this manuscript."/>
  <result pre="bindingLancet20203951022456557432007145 2.CallawayECyranoskiDMallapatySStoyeETollefsonJThe coronavirus pandemic in five powerful chartsNature2020579780048248332203366 3.Centers for" exact="Disease" post="Control and Prevention. Cases in the US. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcases-in-us.html. Accessed"/>
  <result pre="a perspectiveCurr Top Microbiol Immunol2005287315515609508 9.BelkaidYRouseBTNatural regulatory T cells in" exact="infectious" post="diseaseNat Immunol20056435336015785761 10.ChannappanavarRPerlmanSPathogenic human coronavirus infections: causes and consequences"/>
  <result pre="illness in native and immunosuppressed states: a clinical-therapeutic staging proposalJ" exact="Heart" post="Lung Transplant202039540540732362390 12.DongEDuHGardnerLAn interactive web-based dashboard to track COVID-19"/>
  <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA20203231110611069 17.ZhouFYuTDuRFanGLiuYLiuZet al.Clinical course and risk factors"/>
  <result pre="ChinaJAMA20203231110611069 17.ZhouFYuTDuRFanGLiuYLiuZet al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
  <result pre="studyLancet2020395102291054106232171076 18.GuoTFanYChenMWuXZhangLHeTWangHWanJWangXLuZCardiovascular implications of fatal outcomes of patients with coronavirus" exact="disease" post="2019 (COVID-19)JAMA Cardiol201910.1001/jamacardio.2020.101730673084 19.ChenLLiXChenMFengYXiongCThe ACE2 expression in human heart"/>
  <result pre="coronavirus disease 2019 (COVID-19)JAMA Cardiol201910.1001/jamacardio.2020.101730673084 19.ChenLLiXChenMFengYXiongCThe ACE2 expression in human" exact="heart" post="indicates new potential mechanism of heart injury among patients"/>
  <result pre="ACE2 expression in human heart indicates new potential mechanism of" exact="heart" post="injury among patients infected with SARS-CoV-2Cardiovasc Res202011661097110032227090 20.OuditGYKassiriZJiangCLiuPPPoutanenSMPenningerJMet al.SARScoronavirus"/>
  <result pre="SARSEur J Clin Invest200939761862519453650 21.LauerSAGrantzKHBiQJonesFKZhengQMeredithHRet al.The incubation period of coronavirus" exact="disease" post="2019 (COVID-19) from publicly reported confirmed cases: estimation and"/>
  <result pre="al.Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected" exact="disease" post="2019 (COVID-19) with gastrointestinal symptomsGut20206961002100932213556 23.LechienJRChiesa-EstombaCMDe SiatiDRHoroiMLe BonSDRodriguezAet al.Olfactory"/>
  <result pre="as a clinical presentation of mild-to-moderate forms of the coronavirus" exact="disease" post="(COVID-19): a multicenter European studyEur Arch Otorhinolaryngol.202010.1007/s00405-020-05965-132494948 24.ShiSQinMShenBet al.Association"/>
  <result pre="tertiary hospitals in Hubei ProvinceChin Med J (Engl)202013391025103110.1097/CM9.000000000000074432044814 26.KwongJCSchwartzKLCampitelliMAChungHCrowcroftNSKarnauchowTet al.Acute" exact="myocardial infarction" post="after laboratory-confirmed influenza infectionN Engl J Med2018378434535329365305 27.BandyopadhyayDAshishKGhoshSHajraAModiVACardiovascular implications"/>
  <result pre="virus infectionEur J Intern Med201852e35e3629657107 28.YuCMWongRSWuEBKongSLWongJYipGWet al.Cardiovascular complications of severe" exact="acute" post="respiratory syndromePostgrad Med J20068296414014416461478 29.LiBYangJZhaoFZhiLWangXLiuLBiZZhaoYPrevalence and impact of cardiovascular"/>
  <result pre="infectionEur J Intern Med201852e35e3629657107 28.YuCMWongRSWuEBKongSLWongJYipGWet al.Cardiovascular complications of severe acute" exact="respiratory" post="syndromePostgrad Med J20068296414014416461478 29.LiBYangJZhaoFZhiLWangXLiuLBiZZhaoYPrevalence and impact of cardiovascular metabolic"/>
  <result pre="severe acute respiratory syndromePostgrad Med J20068296414014416461478 29.LiBYangJZhaoFZhiLWangXLiuLBiZZhaoYPrevalence and impact of" exact="cardiovascular" post="metabolic diseases on COVID-19 in ChinaClin Res Cardiol2020109553153832161990 30.ChenNZhouMDongXQuJGongFHanYet"/>
  <result pre="acute respiratory syndromePostgrad Med J20068296414014416461478 29.LiBYangJZhaoFZhiLWangXLiuLBiZZhaoYPrevalence and impact of cardiovascular" exact="metabolic diseases" post="on COVID-19 in ChinaClin Res Cardiol2020109553153832161990 30.ChenNZhouMDongXQuJGongFHanYet al.Epidemiological and"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet20203951022350751332007143 31.ZhangJJDongXCaoYYYuanYDYangYBYanYQet al.Clinical characteristics"/>
  <result pre="of 140 patients infected with SARS-CoV-2 in Wuhan, ChinaAllergy202010.1111/all.1423832562554 32.WangLHeWYuXHuDBaoMLiuHZhouJJiangHCoronavirus" exact="disease" post="2019 in elderly patients: characteristics and prognostic factors based"/>
  <result pre="severity and improve the prognosis of patients with novel coronavirus" exact="disease" post="(COVID-19)J Intern Med.202010.1111/joim.1306332220033 34.ChenTWuDChenHYanWYangDChenGet al.Clinical characteristics of 113 deceased"/>
  <result pre="Med.202010.1111/joim.1306332220033 34.ChenTWuDChenHYanWYangDChenGet al.Clinical characteristics of 113 deceased patients with coronavirus" exact="disease" post="2019: retrospective studyBMJ2020368m109132217556 35.LiangWHGuanWJLiCCet al.Clinical characteristics and outcomes of"/>
  <result pre="features and short-term outcomes of 102 patients with corona virus" exact="disease" post="2019 in Wuhan, ChinaClin Infect Dis.202010.1093/cid/ciaa24332521000 38.ShaoFXuSMaXXuZLyuJNgMet al.In-hospital cardiac"/>
  <result pre="virus disease 2019 in Wuhan, ChinaClin Infect Dis.202010.1093/cid/ciaa24332521000 38.ShaoFXuSMaXXuZLyuJNgMet al.In-hospital" exact="cardiac arrest" post="outcomes among patients with COVID-19 pneumonia in Wuhan, ChinaResuscitation2020151182332283117"/>
  <result pre="Dis.202010.1093/cid/ciaa24332521000 38.ShaoFXuSMaXXuZLyuJNgMet al.In-hospital cardiac arrest outcomes among patients with COVID-19" exact="pneumonia" post="in Wuhan, ChinaResuscitation2020151182332283117 39.RichardsonSHirschJSNarasimhanMCrawfordJMMcGinnTDavidsonKWet al.Presenting characteristics, comorbidities, and outcomes"/>
  <result pre="the Lombardy Region, ItalyJAMA20203231615741581 42.TersalviGVicenziMCalabrettaDBiascoLPedrazziniGWintertonDElevated troponin in patients with Coronavirus" exact="Disease" post="2019 (COVID-19): possible mechanismsJ Card Fail.202010.1016/j.cardfail.2020.04.00932315733 43.YaoXHLiTYHeZCPingYFLiuHWYuSCet al.A pathological"/>
  <result pre="Emerg Med.202010.1016/j.ajem.2020.04.04832534874 45.RivaraMBBajwaEKJanuzziJLGongMNThompsonBTChristianiDCPrognostic significance of elevated cardiac troponin-T levels in" exact="acute" post="respiratory distress syndrome patientsPLoS ONE201277e4051522808179 46.BajwaEKBoycePDJanuzziJLGongMNThompsonBTChristianiDCBiomarker evidence of myocardial"/>
  <result pre="Med.202010.1016/j.ajem.2020.04.04832534874 45.RivaraMBBajwaEKJanuzziJLGongMNThompsonBTChristianiDCPrognostic significance of elevated cardiac troponin-T levels in acute" exact="respiratory" post="distress syndrome patientsPLoS ONE201277e4051522808179 46.BajwaEKBoycePDJanuzziJLGongMNThompsonBTChristianiDCBiomarker evidence of myocardial cell"/>
  <result pre="significance of elevated cardiac troponin-T levels in acute respiratory distress" exact="syndrome" post="patientsPLoS ONE201277e4051522808179 46.BajwaEKBoycePDJanuzziJLGongMNThompsonBTChristianiDCBiomarker evidence of myocardial cell injury is"/>
  <result pre="evidence of myocardial cell injury is associated with mortality in" exact="acute" post="respiratory distress syndromeCrit Care Med200735112484249018084839 47.DuRHLiangLRYangCQWangWCaoTZLiMet al.Predictors of mortality"/>
  <result pre="of myocardial cell injury is associated with mortality in acute" exact="respiratory" post="distress syndromeCrit Care Med200735112484249018084839 47.DuRHLiangLRYangCQWangWCaoTZLiMet al.Predictors of mortality for"/>
  <result pre="Care Med200735112484249018084839 47.DuRHLiangLRYangCQWangWCaoTZLiMet al.Predictors of mortality for patients with COVID-19" exact="pneumonia" post="caused by SARS-CoV-2: a prospective cohort studyEur Respir J.2020555200052432269088"/>
  <result pre="SARS-CoV-2: a prospective cohort studyEur Respir J.2020555200052432269088 48.HanHXieLLiuRYangJLiuFWuKet al.Analysis of" exact="heart" post="injury laboratory parameters in 273 COVID-19 patients in one"/>
  <result pre="novel coronavirus diseaseJ Infect.202010.1016/j.jinf.2020.03.02132540459 51.LiJWHanTWWoodwardMAndersonCSZhouHChenYDNealBThe impact of novel coronavirus on" exact="heart" post="injury: a systematic review and meta-analysisProg Cardiovasc Dis.202010.1016/j.pcad.2020.04.00832305557 52.LippiGLavieCJSanchis-GomarFCardiac"/>
  <result pre="meta-analysisProg Cardiovasc Dis.202010.1016/j.pcad.2020.04.00832305557 52.LippiGLavieCJSanchis-GomarFCardiac troponin I in patients with coronavirus" exact="disease" post="2019 (COVID-19): evidence from a meta-analysisProg Cardiovasc Dis.202010.1016/j.pcad.2020.03.00132224113 53.ZengJHLiuYXYuanJWangFXWuWBLiJXet"/>
  <result pre="complicated with fulminant myocarditis: a case report and insightsInfection202010.1007/s15010-020-01424-532277408 54.HuaAO'GallagherKSadoDByrneJLife-threatening" exact="cardiac tamponade" post="complicating myo-pericarditis in COVID-19Eur Heart J.202010.1093/eurheartj/ehaa25332227076 55.DabbaghMFDâ€™SouzaPWeinmannAJBhargavaPBasirMBCardiac Tamponade Secondary"/>
  <result pre="report and insightsInfection202010.1007/s15010-020-01424-532277408 54.HuaAO'GallagherKSadoDByrneJLife-threatening cardiac tamponade complicating myo-pericarditis in COVID-19Eur" exact="Heart" post="J.202010.1093/eurheartj/ehaa25332227076 55.DabbaghMFDâ€™SouzaPWeinmannAJBhargavaPBasirMBCardiac Tamponade Secondary to COVID-19JACC Case Rep.202010.1016/j.jaccas.2020.04.00932328588 56.MeyerPDegrauweSVan"/>
  <result pre="cardiac tamponade complicating myo-pericarditis in COVID-19Eur Heart J.202010.1093/eurheartj/ehaa25332227076 55.DabbaghMFDâ€™SouzaPWeinmannAJBhargavaPBasirMBCardiac Tamponade" exact="Secondary" post="to COVID-19JACC Case Rep.202010.1016/j.jaccas.2020.04.00932328588 56.MeyerPDegrauweSVan DeldenCGhadriJRTemplinCTypical Takotsubo syndrome triggered"/>
  <result pre="55.DabbaghMFDâ€™SouzaPWeinmannAJBhargavaPBasirMBCardiac Tamponade Secondary to COVID-19JACC Case Rep.202010.1016/j.jaccas.2020.04.00932328588 56.MeyerPDegrauweSVan DeldenCGhadriJRTemplinCTypical Takotsubo" exact="syndrome" post="triggered by SARS-CoV-2 infectionEur Heart J20204119186032285915 57.MinhasASScheelPGaribaldiBLiuGHortonMJenningsMJonesSRMichosEDHaysAGTakotsubo Syndrome in"/>
  <result pre="Case Rep.202010.1016/j.jaccas.2020.04.00932328588 56.MeyerPDegrauweSVan DeldenCGhadriJRTemplinCTypical Takotsubo syndrome triggered by SARS-CoV-2 infectionEur" exact="Heart" post="J20204119186032285915 57.MinhasASScheelPGaribaldiBLiuGHortonMJenningsMJonesSRMichosEDHaysAGTakotsubo Syndrome in the Setting of COVID-19 InfectionJACC"/>
  <result pre="DeldenCGhadriJRTemplinCTypical Takotsubo syndrome triggered by SARS-CoV-2 infectionEur Heart J20204119186032285915 57.MinhasASScheelPGaribaldiBLiuGHortonMJenningsMJonesSRMichosEDHaysAGTakotsubo" exact="Syndrome" post="in the Setting of COVID-19 InfectionJACC Case Rep.202010.1016/j.jaccas.2020.04.02332363351 58.HarikrishnanSMohananPPChopraVKAmbujRSanjayGManishBet"/>
  <result pre="Rep.202010.1016/j.jaccas.2020.04.02332363351 58.HarikrishnanSMohananPPChopraVKAmbujRSanjayGManishBet al.Cardiological society of India position statement on COVID-19" exact="and heart" post="failureIndian Heart J.202010.1016/j.ihj.2020.04.01232405088 59.TamCFCheungKSLamSWongAYungASzeMet al.Impact of coronavirus disease 2019"/>
  <result pre="58.HarikrishnanSMohananPPChopraVKAmbujRSanjayGManishBet al.Cardiological society of India position statement on COVID-19 and" exact="heart" post="failureIndian Heart J.202010.1016/j.ihj.2020.04.01232405088 59.TamCFCheungKSLamSWongAYungASzeMet al.Impact of coronavirus disease 2019"/>
  <result pre="society of India position statement on COVID-19 and heart failureIndian" exact="Heart" post="J.202010.1016/j.ihj.2020.04.01232405088 59.TamCFCheungKSLamSWongAYungASzeMet al.Impact of coronavirus disease 2019 (COVID-19) outbreak"/>
  <result pre="COVID-19 and heart failureIndian Heart J.202010.1016/j.ihj.2020.04.01232405088 59.TamCFCheungKSLamSWongAYungASzeMet al.Impact of coronavirus" exact="disease" post="2019 (COVID-19) outbreak on ST-Segment-Elevation Myocardial Infarction Care in"/>
  <result pre="al.Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-Segment-Elevation Myocardial" exact="Infarction" post="Care in Hong Kong, ChinaCirc Cardiovasc Qual Outcomes2020134e00663132182131 60.ParkJChoiKHLeeJMKimHKHwangDRheeTMet"/>
  <result pre="time and onset-to-door time on mortality in patients with ST-segment-elevation" exact="myocardial infarction" post="treated with primary percutaneous coronary interventionJ Am Heart Assoc201989e01218831041869"/>
  <result pre="on mortality in patients with ST-segment-elevation myocardial infarction treated with" exact="primary" post="percutaneous coronary interventionJ Am Heart Assoc201989e01218831041869 61.WeltFGPShahPBAronowHDBortnickAEHenryTDSherwoodMWet al.Catheterization laboratory"/>
  <result pre="ST-segment-elevation myocardial infarction treated with primary percutaneous coronary interventionJ Am" exact="Heart" post="Assoc201989e01218831041869 61.WeltFGPShahPBAronowHDBortnickAEHenryTDSherwoodMWet al.Catheterization laboratory considerations during the coronavirus (COVID-19)"/>
  <result pre="ACC's Interventional Council and SCAIJ Am Coll Cardiol202075182372237532199938 62.TettSCutlerDDayRAntimalarials in" exact="rheumatic" post="diseasesBaillieres Clin Rheumatol1990434674892093438 63.JonesSKOcular toxicity and hydroxychloroquine: guidelines for"/>
  <result pre="and hydroxychloroquine: guidelines for screeningBr J Dermatol199914013710215761 64.LakkireddyDRChungMKGopinathannairRPattonKKGluckmanTJTuragamMet al.Guidance for" exact="Cardiac" post="Electrophysiology During the Coronavirus (COVID-19) Pandemic from the Heart"/>
  <result pre="for Cardiac Electrophysiology During the Coronavirus (COVID-19) Pandemic from the" exact="Heart" post="Rhythm Society COVID-19 Task Force; Electrophysiology Section of the"/>
  <result pre="Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the" exact="American" post="College of Cardiology; and the Electrocardiography and Arrhythmias Committee"/>
  <result pre="of the American College of Cardiology; and the Electrocardiography and" exact="Arrhythmias" post="Committee of the Council on Clinical Cardiology, American Heart"/>
  <result pre="Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology," exact="American" post="Heart AssociationHeart Rhythm202010.1016/j.hrthm.2020.03.02832540298 65.American College of Cardiology. Ventricular arrhythmia"/>
  <result pre="and Arrhythmias Committee of the Council on Clinical Cardiology, American" exact="Heart" post="AssociationHeart Rhythm202010.1016/j.hrthm.2020.03.02832540298 65.American College of Cardiology. Ventricular arrhythmia risk"/>
  <result pre="Clinical Cardiology, American Heart AssociationHeart Rhythm202010.1016/j.hrthm.2020.03.02832540298 65.American College of Cardiology." exact="Ventricular" post="arrhythmia risk due to hydroxychloroquine-azithromycin treatment for COVID-19. https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19."/>
  <result pre="Cardiology, American Heart AssociationHeart Rhythm202010.1016/j.hrthm.2020.03.02832540298 65.American College of Cardiology. Ventricular" exact="arrhythmia" post="risk due to hydroxychloroquine-azithromycin treatment for COVID-19. https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19. Accessed"/>
  <result pre="hospital setting or a clinical trial due to risk of" exact="heart" post="rhythm problems. Available online from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or. Accessed 9 June"/>
  <result pre="Accessed 9 June 2020. 67.EdelsonDPSassonCChanPSAtkinsDLAzizKBeckerLBet al.Interim Guidance for Basic and" exact="Advanced" post="Life Support in Adults, Children, and Neonates with Suspected"/>
  <result pre="the Emergency Cardiovascular Care Committee and Get with the GuidelinesÂ®-Resuscitation" exact="Adult" post="and Pediatric Task Forces of the American Heart Association"/>
  <result pre="Cardiovascular Care Committee and Get with the GuidelinesÂ®-Resuscitation Adult and" exact="Pediatric" post="Task Forces of the American Heart Association in Collaboration"/>
  <result pre="with the GuidelinesÂ®-Resuscitation Adult and Pediatric Task Forces of the" exact="American" post="Heart Association in Collaboration with the American Academy of"/>
  <result pre="the GuidelinesÂ®-Resuscitation Adult and Pediatric Task Forces of the American" exact="Heart" post="Association in Collaboration with the American Academy of Pediatrics,"/>
  <result pre="Forces of the American Heart Association in Collaboration with the" exact="American" post="Academy of Pediatrics, American Association for Respiratory Care, American"/>
  <result pre="Heart Association in Collaboration with the American Academy of Pediatrics," exact="American" post="Association for Respiratory Care, American College of Emergency Physicians,"/>
  <result pre="Collaboration with the American Academy of Pediatrics, American Association for" exact="Respiratory" post="Care, American College of Emergency Physicians, The Society of"/>
  <result pre="the American Academy of Pediatrics, American Association for Respiratory Care," exact="American" post="College of Emergency Physicians, The Society of Critical Care"/>
  <result pre="of Emergency Physicians, The Society of Critical Care Anesthesiologists, and" exact="American" post="Society of Anesthesiologists Circulation: Supporting Organizations: American Association of"/>
  <result pre="Care Anesthesiologists, and American Society of Anesthesiologists Circulation: Supporting Organizations:" exact="American" post="Association of Critical Care Nurses and National EMS PhysiciansCirculation202010.1161/CIRCULATIONAHA.120.04746332270695"/>
  <result pre="69.TangNBaiHChenXGongJLiDSunZAnticoagulant treatment is associated with decreased mortality in severe coronavirus" exact="disease" post="2019 patients with coagulopathyJ Thromb Haemost20201851094109932220112 70.PanigadaMBottinoNTagliabuePGrasselliGNovembrinoCChantarangkulVet al.Hypercoagulability of"/>
  <result pre="Time to change the paradigm of computed tomographyThromb Res2020190585932302782 73.CaseyKIteenANicoliniRAutenJCOVID-19" exact="pneumonia" post="with hemoptysis: acute segmental pulmonary emboli associated with novel"/>
  <result pre="the paradigm of computed tomographyThromb Res2020190585932302782 73.CaseyKIteenANicoliniRAutenJCOVID-19 pneumonia with hemoptysis:" exact="acute" post="segmental pulmonary emboli associated with novel coronavirus infectionAm J"/>
  <result pre="of computed tomographyThromb Res2020190585932302782 73.CaseyKIteenANicoliniRAutenJCOVID-19 pneumonia with hemoptysis: acute segmental" exact="pulmonary" post="emboli associated with novel coronavirus infectionAm J Emerg Med.202010.1016/j.ajem.2020.04.01132312574"/>
  <result pre="factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic" exact="pulmonary" post="embolismExp Clin Cardiol201318212923940438 75.KolliasAKyriakoulisKGDimakakosEPoulakouGStergiouGSSyrigosKThromboembolic risk and anticoagulant therapy in"/>
  <result pre="Moore EE. ISTH interim guidance on recognition and management of" exact="coagulopathy" post="in COVID-19: a comment. J Thromb Haemost. 2020. 77.ThachilJThe"/>
  <result pre="Haemost.202010.1111/jth.1486032558075 78.WangJHajizadehNMooreEEMcIntyreRCMoorePKVeressLAet al.Tissue plasminogen activator (tPA) treatment for COVID-19 associated" exact="acute" post="respiratory distress syndrome (ARDS): a case seriesJ Thromb Haemost.202010.1111/jth.1482832302435"/>
  <result pre="78.WangJHajizadehNMooreEEMcIntyreRCMoorePKVeressLAet al.Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute" exact="respiratory" post="distress syndrome (ARDS): a case seriesJ Thromb Haemost.202010.1111/jth.1482832302435 79.ThachilJTangNGandoSFalangaACattaneoMLeviMet"/>
  <result pre="plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress" exact="syndrome" post="(ARDS): a case seriesJ Thromb Haemost.202010.1111/jth.1482832302435 79.ThachilJTangNGandoSFalangaACattaneoMLeviMet al.DOACs and"/>
  <result pre="(ARDS): a case seriesJ Thromb Haemost.202010.1111/jth.1482832302435 79.ThachilJTangNGandoSFalangaACattaneoMLeviMet al.DOACs and 'newer'" exact="haemophilia" post="therapies in COVID-19J Thromb Haemost.202010.1111/jth.1484132558075 80.AsakuraHOgawaHPotential of heparin and"/>
  <result pre="and angiotensin II receptor blockers with mortality among patients with" exact="hypertension" post="hospitalized with COVID-19Circ Res.202010.1161/CIRCRESAHA.120.31713432496914 87.JarchoJAIngelfingerJRHamelMBDâ€™AgostinoRBSrHarringtonDPInhibitors of the reninâ€&quot;angiotensinâ€&quot;aldosterone system"/>
  <result pre="inhibitors with severity or risk of death in patients with" exact="hypertension" post="hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan,"/>
  <result pre="risk of death in patients with hypertension hospitalized for coronavirus" exact="disease" post="2019 (COVID-19) infection in Wuhan, ChinaJAMA Cardiol202010.1001/jamacardio.2020.162432324209 89.GuoJHuangZLinLLvJCoronavirus disease"/>
  <result pre="in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19)" exact="infection" post="in Wuhan, ChinaJAMA Cardiol202010.1001/jamacardio.2020.162432324209 89.GuoJHuangZLinLLvJCoronavirus disease 2019 (COVID-19) and"/>
  <result pre="coronavirus disease 2019 (COVID-19) infection in Wuhan, ChinaJAMA Cardiol202010.1001/jamacardio.2020.162432324209 89.GuoJHuangZLinLLvJCoronavirus" exact="disease" post="2019 (COVID-19) and cardiovascular disease: a viewpoint on the"/>
  <result pre="infection in Wuhan, ChinaJAMA Cardiol202010.1001/jamacardio.2020.162432324209 89.GuoJHuangZLinLLvJCoronavirus disease 2019 (COVID-19) and" exact="cardiovascular" post="disease: a viewpoint on the potential influence of angiotensin-converting"/>
  <result pre="enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe" exact="acute" post="respiratory syndrome coronavirus 2 infectionJ Am Heart Assoc202097e01621932233755 90.Sanchis-GomarFLavieCJPerez-QuilisCHenryBMLippiGAngiotensin-converting"/>
  <result pre="inhibitors/angiotensin receptor blockers on onset and severity of severe acute" exact="respiratory" post="syndrome coronavirus 2 infectionJ Am Heart Assoc202097e01621932233755 90.Sanchis-GomarFLavieCJPerez-QuilisCHenryBMLippiGAngiotensin-converting enzyme"/>
  <result pre="receptor blockers on onset and severity of severe acute respiratory" exact="syndrome" post="coronavirus 2 infectionJ Am Heart Assoc202097e01621932233755 90.Sanchis-GomarFLavieCJPerez-QuilisCHenryBMLippiGAngiotensin-converting enzyme 2"/>
  <result pre="severity of severe acute respiratory syndrome coronavirus 2 infectionJ Am" exact="Heart" post="Assoc202097e01621932233755 90.Sanchis-GomarFLavieCJPerez-QuilisCHenryBMLippiGAngiotensin-converting enzyme 2 and antihypertensives (angiotensin receptor blockers"/>
  <result pre="antihypertensives (angiotensin receptor blockers and angiotensin-converting enzyme inhibitors) in coronavirus" exact="disease" post="2019Mayo Clin Proc.202010.1016/j.mayocp.2020.03.02632376099 91.HajraABandyopadhyayDCOVID-19 and ACEI/ARB: not associated?Am J"/>
  <result pre="and ACEI/ARB: not associated?Am J Hypertens.202010.1093/ajh/hpaa07632415832 92.SandersJMMonogueMLJodlowskiTZCutrellJBpharmacologic treatments for coronavirus" exact="disease" post="2019 (COVID-19): a reviewJAMA20203231818241836 93.US FDA. Kaletra prescribing information."/>
  <result pre="possible therapeutic option for the COVID-19Travel Med Infect Dis20203410161532145386 95.Altered" exact="Lipid Metabolism" post="in Recovered SARS Patients Twelve Years after Infection. Scientific"/>
  <result pre="therapeutic option for the COVID-19Travel Med Infect Dis20203410161532145386 95.Altered Lipid" exact="Metabolism" post="in Recovered SARS Patients Twelve Years after Infection. Scientific"/>
  <result pre="Accessed 15 Apr 2020. 96.HongNDuXKAvascular necrosis of bone in severe" exact="acute" post="respiratory syndromeClin Radiol200459760260815208066 97.ZhangPLiJLiuHHanNJuJKouYet al.Long-term bone and lung consequences"/>
  <result pre="15 Apr 2020. 96.HongNDuXKAvascular necrosis of bone in severe acute" exact="respiratory" post="syndromeClin Radiol200459760260815208066 97.ZhangPLiJLiuHHanNJuJKouYet al.Long-term bone and lung consequences associated"/>
  <result pre="97.ZhangPLiJLiuHHanNJuJKouYet al.Long-term bone and lung consequences associated with hospital-acquired severe" exact="acute" post="respiratory syndrome: a 15-year follow-up from a prospective cohort"/>
  <result pre="al.Long-term bone and lung consequences associated with hospital-acquired severe acute" exact="respiratory" post="syndrome: a 15-year follow-up from a prospective cohort studyBone"/>
  <result pre="Res20208832128276 98.SungPHYangYHChiangHJChiangJYChenCJYipHKet al.Cardiovascular and cerebrovascular events are associated with nontraumatic" exact="osteonecrosis" post="of the femoral headClin Orthop Relat Res2018476486587429480889 99.KangJHLinHCIncreased risk"/>
  <result pre="of the femoral headClin Orthop Relat Res2018476486587429480889 99.KangJHLinHCIncreased risk for" exact="coronary heart disease" post="after avascular necrosis of femoral head: a 3-year follow-up"/>
  <result pre="the femoral headClin Orthop Relat Res2018476486587429480889 99.KangJHLinHCIncreased risk for coronary" exact="heart" post="disease after avascular necrosis of femoral head: a 3-year"/>
  <result pre="femoral headClin Orthop Relat Res2018476486587429480889 99.KangJHLinHCIncreased risk for coronary heart" exact="disease" post="after avascular necrosis of femoral head: a 3-year follow-up"/>
  <result pre="Orthop Relat Res2018476486587429480889 99.KangJHLinHCIncreased risk for coronary heart disease after" exact="avascular necrosis" post="of femoral head: a 3-year follow-up studyAm Heart J.20101595803808e120435189"/>
  <result pre="after avascular necrosis of femoral head: a 3-year follow-up studyAm" exact="Heart" post="J.20101595803808e120435189 100.LamMHWingYKYuMWLeungCMMaRCKongAPet al.Mental morbidities and chronic fatigue in severe"/>
  <result pre="a 3-year follow-up studyAm Heart J.20101595803808e120435189 100.LamMHWingYKYuMWLeungCMMaRCKongAPet al.Mental morbidities and" exact="chronic" post="fatigue in severe acute respiratory syndrome survivors: long-term follow-upArch"/>
  <result pre="Heart J.20101595803808e120435189 100.LamMHWingYKYuMWLeungCMMaRCKongAPet al.Mental morbidities and chronic fatigue in severe" exact="acute" post="respiratory syndrome survivors: long-term follow-upArch Intern Med2009169222142214720008700 101.DasARoyBSchwarzerGSilvermanMGZieglerOBandyopadhyayDet al.Comparison"/>
  <result pre="J.20101595803808e120435189 100.LamMHWingYKYuMWLeungCMMaRCKongAPet al.Mental morbidities and chronic fatigue in severe acute" exact="respiratory" post="syndrome survivors: long-term follow-upArch Intern Med2009169222142214720008700 101.DasARoyBSchwarzerGSilvermanMGZieglerOBandyopadhyayDet al.Comparison of"/>
  <result pre="100.LamMHWingYKYuMWLeungCMMaRCKongAPet al.Mental morbidities and chronic fatigue in severe acute respiratory" exact="syndrome" post="survivors: long-term follow-upArch Intern Med2009169222142214720008700 101.DasARoyBSchwarzerGSilvermanMGZieglerOBandyopadhyayDet al.Comparison of treatment"/>
  <result pre="long-term follow-upArch Intern Med2009169222142214720008700 101.DasARoyBSchwarzerGSilvermanMGZieglerOBandyopadhyayDet al.Comparison of treatment options for" exact="depression" post="in heart failure: a network meta-analysisJ Psychiatr Res201910872330419488 102.PatelNChakrabortySBandyopadhyayDAmgaiBHajraAAttiVet"/>
  <result pre="Intern Med2009169222142214720008700 101.DasARoyBSchwarzerGSilvermanMGZieglerOBandyopadhyayDet al.Comparison of treatment options for depression in" exact="heart" post="failure: a network meta-analysisJ Psychiatr Res201910872330419488 102.PatelNChakrabortySBandyopadhyayDAmgaiBHajraAAttiVet al.Association between"/>
  <result pre="heart failure: a network meta-analysisJ Psychiatr Res201910872330419488 102.PatelNChakrabortySBandyopadhyayDAmgaiBHajraAAttiVet al.Association between" exact="depression" post="and readmission of heart failure: a national representative database"/>
  <result pre="meta-analysisJ Psychiatr Res201910872330419488 102.PatelNChakrabortySBandyopadhyayDAmgaiBHajraAAttiVet al.Association between depression and readmission of" exact="heart" post="failure: a national representative database studyProg Cardiovasc Dis.202010.1016/j.pcad.2020.03.01432224112 103.De"/>
  <result pre="representative database studyProg Cardiovasc Dis.202010.1016/j.pcad.2020.03.01432224112 103.De HertMDetrauxJVancampfortDThe intriguing relationship between" exact="coronary heart disease" post="and mental disordersDialogues Clin Neurosci2018201314029946209 104.BozziniSAlbergatiACapelliELorussoLGazzarusoCPelisseroGet al.Cardiovascular characteristics of"/>
  <result pre="database studyProg Cardiovasc Dis.202010.1016/j.pcad.2020.03.01432224112 103.De HertMDetrauxJVancampfortDThe intriguing relationship between coronary" exact="heart" post="disease and mental disordersDialogues Clin Neurosci2018201314029946209 104.BozziniSAlbergatiACapelliELorussoLGazzarusoCPelisseroGet al.Cardiovascular characteristics"/>
  <result pre="studyProg Cardiovasc Dis.202010.1016/j.pcad.2020.03.01432224112 103.De HertMDetrauxJVancampfortDThe intriguing relationship between coronary heart" exact="disease" post="and mental disordersDialogues Clin Neurosci2018201314029946209 104.BozziniSAlbergatiACapelliELorussoLGazzarusoCPelisseroGet al.Cardiovascular characteristics of"/>
  <result pre="disease and mental disordersDialogues Clin Neurosci2018201314029946209 104.BozziniSAlbergatiACapelliELorussoLGazzarusoCPelisseroGet al.Cardiovascular characteristics of" exact="chronic" post="fatigue syndromeBiomed Rep201881263029399336 105.StahelPFHow to risk-stratify elective surgery during"/>
  <result pre="Covid-19 outbreak in Northern ItalyN Engl J Med.202010.1056/NEJMc200916632343497 109.BaldiESechiGMMareCCanevariFBrancaglioneAPrimiRet al.Out-of-hospital" exact="cardiac arrest" post="during the Covid-19 outbreak in ItalyN Engl J Med.202010.1056/NEJMc201041832348640"/>
 </snippets>
</snippetsTree>
